Gadoteridol Patent Expiration
Gadoteridol is Used for enhancing visibility of tissues and organs during magnetic resonance imaging. It was first introduced by Bracco Diagnostics Inc
Gadoteridol Patents
Given below is the list of patents protecting Gadoteridol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Prohance | US5846519 | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec 08, 2015
(Expired) | Bracco |
| Prohance Multipack | US5846519 | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec 08, 2015
(Expired) | Bracco |
| Prohance | US5474756 | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec 12, 2012
(Expired) | Bracco |
| Prohance | US6143274 | Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec 12, 2012
(Expired) | Bracco |
| Prohance Multipack | US5474756 | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec 12, 2012
(Expired) | Bracco |
| Prohance Multipack | US6143274 | Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec 12, 2012
(Expired) | Bracco |
Gadoteridol's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Gadoteridol:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI | University of Alabama at Birmingham | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |